top of page
Copy of Vibrant IP.png

VIP-3640

IPdR Radiosensitization Platform

Oral IPdR radiosensitization, designed to increase tumor sensitivity and enhance radiation therapy across multiple cancer types.

  • This patent portfolio covers an oral radiosensitization therapy designed to enhance the effectiveness of radiation treatment for cancer. The technology uses 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR), an oral prodrug that is converted in the body into iododeoxyuridine (IUdR). IUdR can be incorporated into tumor-cell DNA, increasing cancer cells’ susceptibility to radiation-induced damage and potentially improving tumor control without requiring higher radiation doses.


    The patented methods replace direct IUdR delivery—which can require prolonged continuous intravenous infusion and is limited by systemic toxicity and a narrow therapeutic window—with orally administered IPdR. This approach may provide a more practical and patient-friendly method of radiosensitization that can be integrated into established cancer-treatment protocols without relying on continuous IV administration.


    The granted patents cover methods combining oral IPdR with radiation therapy and chemotherapy, including specified therapeutic agents, cancer settings, and radiation modalities. The technology has potential applications across multiple cancer types, including brain and gastrointestinal cancers, and may be used alongside advanced radiation techniques such as intensity-modulated radiation therapy, stereotactic radiosurgery, stereotactic body radiation therapy, proton therapy, and carbon-ion therapy. The patent specifications also describe biomarker-based measurement of IUdR incorporation into tumor and normal-tissue DNA to help assess radiosensitization, guide treatment planning, and identify patients most likely to benefit.


    IPdR has undergone extensive preclinical evaluation, including pharmacokinetic, toxicology, DNA-incorporation, and tumor-radiosensitization studies. Animal comparisons described in the patents reported greater tumor radiosensitization with less normal-tissue toxicity than continuous intravenous IUdR. A first-in-human Phase 0 study also found that oral IPdR achieved adequate systemic levels of the active IUdR metabolite, establishing oral feasibility and supporting subsequent clinical evaluation. Later development included multiple Phase I studies and a sponsor-led Phase II glioblastoma study that was terminated in 2025 after the sponsor decided to wind down the program.


    Potential commercial applications include cancer radiosensitization, combination chemoradiation, brain and gastrointestinal cancer treatment, precision radiation oncology, patient selection, and radiation-treatment optimization.


    The intellectual property is available for sale, licensing, or joint development, with consulting in various fields of use.

  • The IP and assets available for sale, license, or joint development include:

    • US11058702

    • US20170266217

    • WO2016057699

    • EP3204043

  • Other Public Data Room Materials Available at VIP-3640  Public Data Room for IPdR Radiosensitization Platform:

    • Introductory Materials

    • Patents and Applications

    • Patent File Histories

    • Patent Assignments and Ownership

    • Market Analysis

    Additional Materials (available upon signing a mutual non-disclosure agreement):

    • Due Diligence Review

    • CMC/Manufacturing Documents

    • Valuation Report

    • FDA Documents

  • Pricing guidance for this transaction may be available. All parties interested in the IP above are authorized to contact Charlette Hunter at Vibrant IP, LLC at charlette@vibrantip.com and +1 404-482-3652.

bottom of page